For the first time, global funding for neglected disease R&D grew for three consecutive years, reaching a record high of more than US$4.05 billion in 2018.
Increases from both the public and private sectors drove a 7.9% ($290m) rise in total global funding compared to the previous year. Investment over the past several years has translated into a robust innovation pipeline with more than 500 candidates in development, though not all diseases are receiving the investments in R&D they need.
This is according to the 12th annual G-FINDER report, which was launched today in Brussels by Policy Cures Research. G-FINDER is the world's most comprehensive survey of R&D funding for neglected infectious diseases, which disproportionately affect people in developing countries.
The positive impact of sustained, record-breaking growth in R&D funding for the world's most vulnerable people can't be understated. The upward trend in investment driven by industry and the public sector provides hope for a future where no one lacks access to the vaccines, medicines and products they need to thrive. But at the same time, we can't overlook the fact that progress is uneven and funding gaps remain." Dr. Nick Chapman, lead author, G-FINDER Industry accelerates global investment
The private sector made its largest-ever investment in neglected disease R&D to comprise 17% ($694m) of total funding in 2018. This growth represented a 20% ($118m) jump from the previous year and was solely driven by increased investments ($598m, up $132m) from multinational pharmaceutical companies (MNCs).
The collective contributions of MNCs have significantly closed the gap between industry and philanthropy in global funding shares.
The public sector also contributed record levels of investment ($2.59b) and remained the largest source of neglected disease R&D funding.
Though strong growth from industry in 2018 led to a marginal decrease in the public sector's total share of funding, down to its lowest ever level of 64%, investment levels remained high.
High-income countries provided the vast majority (93%) of public funding, and the top three funders all increased investment for the second year in a row.
The United States provided 71% ($1.77b) of total neglected disease research funding, the United Kingdom provided 9.2% thanks to its largest-ever contribution of $230 million and the European Commission provided 5.4% ($134m).
Funding from low- and middle-income country (LMIC) governments fell by 7.6% ($7.9m) to $95 million in 2018. However, this followed a year of record-breaking investment from India in 2017. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology